StocksMedium•12 November 2026•
1 min read
Century Therapeutics Beats Q3 Earnings Estimates with Narrower Loss
Key Facts
1Century Therapeutics reported a GAAP EPS loss of $0.11, beating analyst estimates by $0.01.
Century Therapeutics reported a GAAP EPS loss of $0.11 for the third quarter ending September 2026. Seeking Alpha reported that these results beat analyst estimates by $0.01, as the company’s financial release showed a narrower-than-expected loss for the fiscal period.
Cash, cash equivalents, and investments for Century Therapeutics stood at $174.1 million as of September 30, 2026, up from $117.1 million on December 31, 2025. The stock IPSC closed at $1.74 on November 11, 2026, and the company estimates its current cash position will support business operations into the first quarter of 2029.